Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-16
2007-10-16
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
09854142
ABSTRACT:
This invention pertains to the discovery that nerve growth factor (NGF) is capable of preventing further demyelination of nervous tissue in pathologies characterized by the demyelination of nervous tissue (e.g. multiple sclerosis). In one embodiment, this invention provides a method for inhibiting demyelination in a subject having an inflammatory disease of a nervous tissue. The method involves administering an effective amount of NGF, an NGF analogue, or an active fragment of NGF where the effective amount is sufficient to downregulate the production of interferon λ by T cells infiltrating the central nervous system and/or to upregulate IL-10 production by glial cells.
REFERENCES:
patent: 5210185 (1993-05-01), Della Valle et al.
patent: 5904144 (1999-05-01), Hammang et al.
patent: 5935577 (1999-08-01), Weiner et al.
patent: 6268340 (2001-07-01), Unger et al.
patent: 731108 (1996-09-01), None
patent: WO 9303140 (1993-02-01), None
patent: WO 97/17087 (1997-05-01), None
patent: WO 9846254 (1998-10-01), None
Diaz-Villoslada et al. (Mar., 1997) Neurology, 48(3) Supp. [2], “Recombinant Human Nerve Growth Factor Prevents Autoimmune Demyelination in Marmosets”, p. 15001, Abstract 142-143.
Diaz-Villoslada et al. (Oct. 13-16, 1996) American Neurology Association Meeting, Miami, FL, USA, “Recombinant Human Nerve Growth Factor Prevents Autoimmune Demyelination in Marmosets”.
Unger et al., Poster presented at the Annual Meeting of the Society for Neuroscience, San Diego, California, Nov. 11-16, 1995, “Time course of regeneration in the adult pig brain following lysolecithin-induced demyelination”.
Angeletti and Bradshaw, (1970)Proc. Natl. Acad. Sci. USA68:2417-2421.
Kandel et al., (1991)Principles of Neural Science, 3rdEdition, Elsevier, p. 22.
Vinken, B., (1970)Handbook of Clinical Neurology 7, Diseases of Nerves, Part I, Chapter 19, pp. 495 et seq.
Althaus, et al., (1992)Neuroscience Letters135:219-223, “Nerve growth factor induces proliferation and enhances fiber regeneration in oligodentrocytes isolated from adult pig brain”.
Gage, et al., (1988)The Journal of Comparative Neurology, 269:147-155, “Morphological respnse of axotomized septal neurons to nerve growth factor”.
Hefti et al, (1984)Brain Research293:305-311, “Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions”.
Hefti, (1986)The Journal of Neuroscience, vol. 6, No. 8, p. 2155-2162, “Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections”.
Crain and Patterson, (1974)Brain Research, 79:145-152, “Enhanced afferent synaptic functions in fetal mouse spinal cord-sensory ganglion explants following NGF-induced ganglion hypertrophy”.
Chun and Patterson, (1977)The Journal of Cell Biology, vol. 75, pp. 596-704, “Role of nerve growth factor in the development of rat sympathetic neurons in vitro—I. Survival, growth and differentiation of catecholomine production”.
Chun and Patterson, (1977)The Journal of Cell Biology, vol. 75, pp. 704-711, “Role of nerve growth factor in the development of rat sympathetic neurons in vitro—II. Developmental studies”.
Levi-Montalcini and Angeletti, (1963)Developmental Biology, 7:653-659, “Essential role of the nerve growth factor in the survival and maintenance of dissociated sensory and sympathetic embryonic nerve cells in vitro”.
Massacesi, et al., (1995)Annals of Neurology, vol. 37, No. 4, pp. 519-530, “Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for muliple sclerosis”.
Althaus et al., (1990)Cellular and Molecular Biology of Myelination, Monastery Ohrbeck, FRG, Aug. 28-Sep. 2, 1989; NATO ASI Series, vol. H43, edited by G. Jeserich et al., Springer Verlag Berlin Heidelberg 1990; pp. 247-253 “Protein kinases A and C are involved in oligodentroglial process formation”.
Engel et al., (1994) NeuroReport 5:397-400, “NGF increases [Ca2+]iin regenerating mature oligodendrolial cells”.
Althaus and Siepl, (1997)Cell Tissue Res.287:135-141, “Oligodendrocytes isolated from adult pig brain synthesise and release prostaglandins”.
Diaz-Cintra, et al., (1995)Cell Transplantation, vol. 4, No. 5, pp. 505-513, “Morphometric study of fetal brain transplants in the insular cortex and NGF effects on neuronal and glial development”.
Schmidt-Schulz and Althaus, (1994)Journal of Neurochemistry, 62:1478-1585, “Monogalactosyl diglyceride, a marker for myelination. Activates oligodendroglial protein kinase C”.
Cohen, et al., (1996)The Journal of Neuroscience, vol. 16, No. 20, pp. 6433-6442, “Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes”.
Miller, et al., (1996)Brain Pathology6:331-34, “Central nervous system remyelination—clinical application of basic neuroscience principles”.
Koliatsos, et al., (1990)The Journal of Neuroscience10(12):3801-3813, “Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey”.
McMorris and McKinnon, (1996)Brain Pathology, 6:313-329 “Regulation of oligo dendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease”.
Kramer, et al., (1995)Nature Medicine, vol. 1, No. 11:1162-1166, “Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neritis”.
The Merck Manual of Diagnosis and Therapy: General Medicine. Berkow, ed. vol. 1. 15th edition. (1987) (Merck Sharpe & Dohme Research Laboratories: Rahway, NJ) p. 1091.
Awatsuji et al. (1993) Interleukin-4 and -5 as modulators of nerve growth factor synthesis/secretion in astrocytes. J. Neurosci. Res. 34:539-545.
Laudiero, et al. (1992) Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci. Lett. 147:9-12.
Longo, et al. (1992) Nerve growth factor: actions in the peripheral and central nervous systems. In Fallon J., Loughlin S., eds. Neurotrophic Factors. New York, Academic Press, 209-256.
Webster (1997) Growth factors and myelin regeneration in multiple sclerosis. Mult. Scler. 3:113-120.
Bartke Ilse
Genain Claude
Hauser Stephen
Unger Jurgen
Hanley Susan
Lankford , Jr. Leon B.
Littlepage Paul
Quine I.P. Law Group PC.
The Regents of the University of California
LandOfFree
NGF for the prevention of demyelination in the nervous system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NGF for the prevention of demyelination in the nervous system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NGF for the prevention of demyelination in the nervous system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3901656